All News

Found 4,653 articles

• PTC Therapeutics, Inc. Initiates Phase 2 Study Of PTC124 In Duchenne Muscular Dystrophy

  1/27/2006

• Baxter International, Inc. Reports Financial Results For The Fourth Quarter And Full-Year 2005

  1/26/2006

• Baxter International, Inc. Mourns Passing Of William B. Graham, Pioneer And Long-Time Leader In Healthcare

  1/25/2006

• Biovitrum AB And Syntonix Pharmaceuticals, Inc. Enter Agreement For The Joint Development And Commercialization Of Recombinant Factor IX For The Treatment Of Hemophilia

  1/23/2006

• Baxter International, Inc. Fourth Quarter And Full Year 2005 Financial Results Conference Call

  1/23/2006

• Bayer HealthCare Introduces Kogenate(R) FS With BIO-SET(R) In The United States

  1/20/2006

• Novo Nordisk A/S Downplays Report Tying Drug To Deaths

  1/18/2006

• The Day In Review: Generic Challenges To Big Pharma

  1/18/2006

• Avigen, Inc. Licenses Unique Neuroactive Compound for Disabling Neuromuscular Conditions From Sanochemia

  1/16/2006

• ZLB Behring Announces FDA Approval Of Vivaglobin(R); The First Subcutaneous Immunoglobulin Replacement Therapy Approved In The U.S.

  1/10/2006

• Avigen, Inc. CFO To Resign

  1/10/2006

• Baxter International, Inc. Expands BioSurgery Product Portfolio With FDA 510(k) Marketing Clearance For TricOs T Bone Void Filler

  1/9/2006

• Wyeth Announces Strategic Collaboration With Trubion Pharmaceuticals Inc.

  1/3/2006

• Wyeth Submits New Drug Application For Desvenlafaxine Extended Release (DVS-233) For Depression

  12/23/2005

• PTC Therapeutics, Inc. Initiates Second Phase 2 Study Of PTC124 In Patients With Cystic Fibrosis In Israel

  12/22/2005

• Avigen, Inc.'s Gene Therapy Technology Acquired By Genzyme Corporation

  12/21/2005

• Avigen, Inc. To Hold Conference Call Today To Discuss Genzyme Corporation Acquisition Of Its Gene Therapy Assets

  12/21/2005

• Baxter International, Inc. Names Steven Caffe Vice President Global Regulatory Affairs And Medical Vigilance

  12/20/2005

• Wyeth Pharmaceuticals (New Jersey) Release: New Data Highlight TYGACIL (tigecycline) In Vitro Activity Against Resistant Gram-Negative And Extended-Spectrum Beta-Lactamase-Producing Bacteria

  12/16/2005

• Baxter International, Inc. Fourth Quarter 2005 Financial Results Conference Call

  12/16/2005